KR930006285B1 - 티아졸 유도체의 제조방법 - Google Patents

티아졸 유도체의 제조방법 Download PDF

Info

Publication number
KR930006285B1
KR930006285B1 KR1019860008678A KR860008678A KR930006285B1 KR 930006285 B1 KR930006285 B1 KR 930006285B1 KR 1019860008678 A KR1019860008678 A KR 1019860008678A KR 860008678 A KR860008678 A KR 860008678A KR 930006285 B1 KR930006285 B1 KR 930006285B1
Authority
KR
South Korea
Prior art keywords
group
carbon atoms
compound
synthesis
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019860008678A
Other languages
English (en)
Korean (ko)
Other versions
KR870004009A (ko
Inventor
요시오 하야시
토메이 오구리
마사키 시노다
미키오 쓰쓰이
카즈오 타카하시
히토시 미이다
Original Assignee
미쓰비시카세이 가부시끼가이샤
스즈끼 세이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미쓰비시카세이 가부시끼가이샤, 스즈끼 세이지 filed Critical 미쓰비시카세이 가부시끼가이샤
Publication of KR870004009A publication Critical patent/KR870004009A/ko
Application granted granted Critical
Publication of KR930006285B1 publication Critical patent/KR930006285B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1019860008678A 1985-10-16 1986-10-16 티아졸 유도체의 제조방법 Expired - Fee Related KR930006285B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP60-228912 1985-10-16
JP228912 1985-10-16
JP60228912A JPS62142168A (ja) 1985-10-16 1985-10-16 チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤

Publications (2)

Publication Number Publication Date
KR870004009A KR870004009A (ko) 1987-05-06
KR930006285B1 true KR930006285B1 (ko) 1993-07-12

Family

ID=16883798

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860008678A Expired - Fee Related KR930006285B1 (ko) 1985-10-16 1986-10-16 티아졸 유도체의 제조방법

Country Status (11)

Country Link
US (1) US4902700A (https=)
EP (1) EP0219436B1 (https=)
JP (1) JPS62142168A (https=)
KR (1) KR930006285B1 (https=)
AU (1) AU603343B2 (https=)
CA (1) CA1326034C (https=)
DE (1) DE3689436T2 (https=)
DK (1) DK169128B1 (https=)
HU (1) HU203228B (https=)
SU (1) SU1554763A3 (https=)
UA (1) UA5585A1 (https=)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258395A (en) * 1984-11-12 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Thiazole compounds as inhibitors of SRS-A
JPS63258854A (ja) * 1987-04-16 1988-10-26 Mitsubishi Kasei Corp カルボキシスチレン誘導体およびそれを有効成分とする薬剤
US4895953A (en) * 1987-09-30 1990-01-23 American Home Products Corporation 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
EP0318085A3 (en) * 1987-11-25 1990-03-14 Merck Frosst Canada Inc. Heterazole dialkanoic acids
CA1322004C (en) * 1987-11-25 1993-09-07 Merck Frosst Canada Incorporated Pyridyl styrene dialkanoic acids
US4962117A (en) * 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
US5037840A (en) * 1987-11-25 1991-08-06 Merck Frosst Canada, Inc. Benzothiazoles
US4957932A (en) * 1987-11-25 1990-09-18 Merck Frosst Canada, Inc. Benzoheterazoles
NZ229761A (en) * 1988-07-12 1991-10-25 Ici Pharma Substituted thiazole derivatives for use as inhibitors of enzyme 5-lipoxygenase; pharmaceutical compositions and preparatory processes
EP0355353B1 (en) * 1988-07-15 1994-03-16 F. Hoffmann-La Roche Ag Cycloalkylthiazole derivatives
US5001140A (en) * 1989-04-17 1991-03-19 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5045554A (en) * 1988-11-29 1991-09-03 Monsanto Company Substituted thiazoles and their use as fungicides
JPH02169584A (ja) * 1988-12-22 1990-06-29 Mitsubishi Kasei Corp ビニルチアゾール誘導体およびそれを有効成分とする薬剤
US5089495A (en) * 1989-01-30 1992-02-18 Imperial Chemical Industries Plc Heterocyclic thiazole derivatives and pharmaceutical compositions comprising said derivatives
WO1990011278A1 (fr) * 1989-03-24 1990-10-04 The Green Cross Corporation Composes de thiazole et leurs applications
JPH03173874A (ja) * 1989-09-29 1991-07-29 Mitsubishi Kasei Corp 新規複素環化合物
WO1992000963A1 (fr) * 1990-07-12 1992-01-23 Yoshitomi Pharmaceutical Industries, Ltd. Composes de styryle et leur utilisation comme medicaments
JP2832923B2 (ja) * 1990-07-13 1998-12-09 吉富製薬株式会社 スチリル化合物およびその医薬用途
JP2600644B2 (ja) * 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
DE59310252D1 (de) * 1992-02-05 2002-01-24 Boehringer Ingelheim Pharma Neue Amiderivate, ihre Herstellung und Verwendung als Arzneimittel mit LTB4-antagonistischer Wirkung
CA2132722A1 (en) * 1992-04-10 1993-10-28 Robert Zamboni Benzothiazole-substituted benzyl alcohols as leukotriene antogonists
WO1993021168A1 (en) * 1992-04-10 1993-10-28 Merck Frosst Canada Inc. Thiazole-substituted benzyl alcohols as leukotriene antagonists
DE4219765A1 (de) * 1992-06-17 1993-12-23 Bayer Ag Substituierte (Benzothiazolyl- und Chinoxalyl-methoxy)phenylessigsäurederivate
US5273986A (en) * 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5508408A (en) * 1993-09-10 1996-04-16 Ciba-Geigy Corporation Quinoline compound
AU5347496A (en) * 1995-04-21 1996-11-07 Daiichi Pharmaceutical Co., Ltd. Ethynylthiazole derivative
AU1110497A (en) * 1995-12-14 1997-07-03 Kaken Pharmaceutical Co., Ltd. Thiazole derivatives
US6376671B1 (en) 1997-06-17 2002-04-23 Kaken Pharmaceutical Co., Ltd. 2-sulfamoylbenzoic acid derivatives
ES2273419T3 (es) * 1997-06-17 2007-05-01 Kaken Pharmaceutical Co., Ltd. Derivados del acido 2-sulfamoilbenzoico.
JP2004137284A (ja) * 1997-06-17 2004-05-13 Kaken Pharmaceut Co Ltd ２−スルファモイル安息香酸誘導体
US6083966A (en) * 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
CN1585639A (zh) * 1998-09-21 2005-02-23 佛罗里达大学研究基金会 抗疟疾制剂
EP1214303A1 (en) * 1999-08-31 2002-06-19 Merck & Co., Inc. Heterocyclic compounds and methods of use thereof
DE50009208D1 (de) 1999-11-25 2005-02-17 Ciba Sc Holding Ag Hydroxyphenylvinylthiazole
EP1103180B1 (de) * 1999-11-25 2005-01-12 Ciba SC Holding AG Hydroxyphenylvinylthiazole
DK1182199T3 (da) * 2000-04-03 2009-08-24 Ihara Chemical Ind Co Fremgangsmåde til fremstilling af amicsyre
JPWO2002087589A1 (ja) * 2001-04-26 2004-08-12 第一製薬株式会社 薬剤排出ポンプ阻害薬
US7056917B2 (en) * 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
WO2005034949A1 (en) * 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR20070085371A (ko) 2004-10-16 2007-08-27 아스트라제네카 아베 페녹시 벤즈아미드 화합물의 제조 방법
TR201910900T4 (tr) 2005-04-04 2019-08-21 Univ Florida Desferritiyokin polieter analogları.
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
CA2614746C (en) 2005-07-09 2011-05-10 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
JP4836704B2 (ja) * 2006-08-07 2011-12-14 中国電力株式会社 端子台用保護カバー
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
UY30822A1 (es) 2006-12-21 2008-07-31 Astrazeneca Ab Fnueva forma cristalina de 3-{[5-azetidin-1-ylcabonyl)pyrazin-2-yl]oxy}-5-[1-methylethyloxy]-n-1h-pyrazol-3-ylbenzamida, composiciones conteniéndola, procesos de preparacion y aplicaciones
WO2008115433A1 (en) * 2007-03-15 2008-09-25 University Of Florida Desferrithiocin polyether analogues
CA2732165A1 (en) 2008-08-04 2010-02-11 Astrazeneca Ab Therapeutic agents 414
EP2166006A1 (en) * 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
CA2782797C (en) 2009-10-02 2018-08-07 Avexxin As Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles
EP3620161A1 (en) 2011-12-16 2020-03-11 University of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
CN105102438B (zh) 2013-01-29 2019-04-30 埃维克辛公司 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
AU2014352780A1 (en) 2013-11-22 2016-06-09 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
KR20170140306A (ko) 2015-04-27 2017-12-20 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US11912676B1 (en) 2023-08-29 2024-02-27 King Faisal University N'-[(4-chlorobenzoyl)oxy]-1,3-benzothiazole-2-carboximidamide as an antitumor and antimicrobial compound
US11919873B1 (en) 2023-08-29 2024-03-05 King Faisal University 1,3-benzothiazol-2-yl-N′-(benzoyloxy)ethanimidamide as an antitumor and antimicrobial compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3137655A (en) * 1961-03-21 1964-06-16 Glanzstoff Ag Optical brightening
DE1670908A1 (de) * 1967-08-16 1971-04-29 Hoechst Ag Neue Benzimidazolverbindungen,Verfahren zu ihrer Herstellung und ihre Verwendung als optische Aufhellungsmittel
US3974282A (en) * 1972-11-04 1976-08-10 Beecham Group Limited Hypoglycemic stilbazolte derivatives
DE2331444A1 (de) * 1973-06-20 1975-01-23 Hoechst Ag Neue styryl-benzoxazole, verfahren zu deren herstellung und ihre verwendung als optische aufhellungsmittel
DE3148291A1 (de) * 1981-12-05 1983-06-09 Basf Ag, 6700 Ludwigshafen Harnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
US4594425A (en) * 1984-02-09 1986-06-10 American Home Products Corporation Heterocyclic compounds as antiallergic agents
US4581457A (en) * 1984-09-21 1986-04-08 American Home Products Corporation Heterocyclic sulfonamides

Also Published As

Publication number Publication date
UA5585A1 (uk) 1994-12-28
EP0219436A2 (en) 1987-04-22
HUT47090A (en) 1989-01-30
DE3689436T2 (de) 1994-04-14
HU203228B (en) 1991-06-28
EP0219436A3 (en) 1989-12-27
SU1554763A3 (ru) 1990-03-30
JPS62142168A (ja) 1987-06-25
AU6393086A (en) 1987-04-30
DE3689436D1 (de) 1994-02-03
US4902700A (en) 1990-02-20
AU603343B2 (en) 1990-11-15
EP0219436B1 (en) 1993-12-22
CA1326034C (en) 1994-01-11
JPH057386B2 (https=) 1993-01-28
DK494186D0 (da) 1986-10-15
DK494186A (da) 1987-04-17
DK169128B1 (da) 1994-08-22
KR870004009A (ko) 1987-05-06

Similar Documents

Publication Publication Date Title
KR930006285B1 (ko) 티아졸 유도체의 제조방법
EP0277836B1 (en) Thiazolidinone derivatives, their preparation and their use
US5104889A (en) Thiazole derivatives
RU2161612C2 (ru) Производные азола, фармацевтическая композиция на их основе, промежуточные соединения
RU2095354C1 (ru) Тиазолидиновые соединения, способы их получения, способ снижения содержания сахара в крови у млекопитающих
US4666931A (en) Benzofuran derivatives useful in treating diabetic complications
US5268386A (en) Certain 3,4-dihydro 4-oxospiro [2H-1 benzopyrans] useful for treating hyperuricemia
US4749701A (en) Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing SRS by employing the same
EP1142885B1 (en) 2-(n-cyanoimino)thiazolidin-4-one derivatives
CZ279917B6 (cs) Thiazolidinové sloučeniny obsahující chinonovou skupinu, způsob výroby a farmaceutické prostředky s jejich obsahem
JPS609716B2 (ja) １，２―ベンズインチアゾリン―３―オン類、それらの製造法および医薬としての使用
JP2005538965A (ja) 関節炎を治療するためのｍｍｐ−１３阻害剤としてのチアジン及びオキサジン誘導体
US5900426A (en) Benzothiazole derivatives
EP1020451B1 (en) Anilide compounds and drugs containing the same
DE68916685T2 (de) Mevalonolactone vom Typ Pyrazolopyridin.
US5455267A (en) Chromone derivative, and aldose reductase inhibitor comprising said compound as active component
JPS6399057A (ja) グリシン誘導体
US4243665A (en) 2-Heterocyclylalkyl-6-methoxy-naphthalenes
EP0365194B1 (en) Prodrugs of antiinflammatory 3-acyl-2-oxindole-1-carboxamides
US4745118A (en) Substituted quinazoline-3-oxides providing pharmacological activity
JP3348505B2 (ja) ベンゾオキサジン−３−オン化合物
US6028068A (en) Substituted 6H-1,3,4-thiadiazine-2-amines, the use thereof as anaesthetising, cardiovascular and hypometabolic agents, and a pharmaceutical composition containing them
JPH02169583A (ja) ビニルチアゾール誘導体およびそれを有効成分とする薬剤
JP2518497B2 (ja) 抗脂血剤
CN119823089A (zh) 一种n-苯基-2-氮杂环乙酰胺衍生物及其制备方法与应用

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U11-oth-PR1002

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 19980709

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 19990713

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19990713

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000